Waverley Pharma Inc

Healthcare CA WAVE

0.025CAD
0.01(66.67%)

Last update at 2026-06-22T14:08:00Z

Day Range

0.030.03

LowHigh

52 Week Range

0.010.04

LowHigh

Fundamentals

Previous Close 0.01
Market Cap0.54M
Volume2500
P/E Ratio-
Dividend Yield-%
EBITDA-0.22459M
Revenue TTM1.51M
Revenue Per Share TTM0.03
Gross Profit TTM 0.59M
Diluted EPS TTM-0.01

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Income before tax	-0.94708M	-2.22405M	-0.66408M	-0.79651M	-0.70576M
Minority interest	-	-	-	-	-
Net income	-0.94708M	-2.22405M	-0.66408M	-0.79651M	-0.70576M
Selling general administrative	0.65M	1.13M	1.14M	0.96M	0.84M
Selling and marketing expenses	-	-	-	-	-
Gross profit	0.21M	0.08M	0.28M	0.22M	0.18M
Reconciled depreciation	0.13M	0.43M	0.21M	0.07M	0.00817M
Ebit	-	-	-0.93615M	-0.78683M	-0.70960M
Ebitda	-	-	-0.72404M	-0.71657M	-0.70143M
Depreciation and amortization	-	-	-	-	-
Non operating income net other	-	-	-	-	-
Operating income	-0.74357M	-1.23388M	-0.93615M	-0.78683M	-0.70960M
Other operating expenses	-	-	-	-	-
Interest expense	0.16M	0.08M	-	0.00000M	0.00000M
Tax provision	-	-	-	-	-
Interest income	0.00108M	0.00152M	-	-	0.00539M
Net interest income	-0.16240M	-0.07665M	-0.01664M	-0.00304M	0.00539M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-	-	-
Total revenue	0.48M	0.41M	1.25M	1.75M	1.38M
Total operating expenses	1.22M	1.65M	2.18M	2.54M	2.08M
Cost of revenue	0.26M	0.33M	0.96M	1.53M	1.19M
Total other income expense net	-0.04110M	-0.91351M	0.29M	-0.00664M	-0.00155M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-0.94708M	-2.22405M	-0.66408M	-0.79651M	-0.70576M
Net income applicable to common shares	-	-	-	-0.79651M	-0.70576M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	2.05M	0.95M	2.69M	3.68M	3.49M
Intangible assets	0.40M	0.26M	1.68M	1.76M	1.81M
Earning assets	-	-	-	-	-
Other current assets	-	-	-	-	-
Total liab	4.08M	2.09M	1.60M	1.89M	1.45M
Total stockholder equity	-2.03156M	-1.13674M	1.09M	1.79M	2.04M
Deferred long term liab	-	-	-	-	-
Other current liab	-	-	-	-	-
Common stock	-	-	7.00M	7.00M	7.00M
Capital stock	7.00M	7.00M	7.00M	7.00M	7.00M
Retained earnings	-10.34222M	-9.39514M	-7.17110M	-6.50702M	-5.71051M
Other liab	-	-	-	-	-
Good will	0.22M	-	-	-	-
Other assets	-	-	0.38M	0.48M	-
Cash	0.24M	0.05M	0.13M	0.16M	0.71M
Cash and equivalents	-	-	-	-	-
Total current liabilities	3.86M	2.09M	1.60M	1.89M	1.41M
Current deferred revenue	-	-	-	-	-
Net debt	2.57M	1.55M	0.57M	0.10M	-
Short term debt	-	-	-	-	-
Short long term debt	2.81M	1.60M	0.70M	0.26M	-
Short long term debt total	-	-	-	-	-
Other stockholder equity	-	-	-	0.49M	-0.05591M
Property plant equipment	-	-	-	-	-
Total current assets	0.73M	0.42M	0.63M	1.45M	1.68M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	0.03M	0.23M
Short term investments	-	-	-	-	-
Net receivables	0.05M	0.14M	0.19M	0.70M	0.46M
Long term debt	-	-	-	-	0.04M
Inventory	0.26M	0.00063M	0.06M	0.33M	0.27M
Accounts payable	1.01M	0.49M	0.74M	1.06M	0.83M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	0.43M	0.27M	0.38M	0.48M	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	1.32M	0.54M	2.05M	2.24M	1.81M
Capital lease obligations	0.26M	-	-	-	-
Long term debt total	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Investments	-0.61155M	0.00000M	-0.22662M	-	-
Change to liabilities	-	-	0.00000M	0.23M	0.26M
Total cashflows from investing activities	-	-	-	-	-
Net borrowings	1.20M	0.94M	0.44M	0.22M	0.04M
Total cash from financing activities	1.20M	0.94M	0.44M	0.22M	-0.37366M
Change to operating activities	-	-	-	-0.00589M	-0.20224M
Net income	-0.94708M	-2.22405M	-0.66408M	-0.79651M	-0.70576M
Change in cash	0.18M	-0.08078M	-0.02432M	-0.55238M	-0.76692M
Begin period cash flow	0.05M	0.13M	0.16M	0.71M	1.48M
End period cash flow	0.24M	0.05M	0.13M	0.16M	0.71M
Total cash from operating activities	-0.41019M	-1.02111M	-0.23706M	-0.79878M	-0.36170M
Issuance of capital stock	-	-	-	-	-
Depreciation	0.13M	0.43M	0.21M	0.03M	0.00817M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-0.02885M	0.06M	0.29M	-0.06451M	-0.17793M
Change to account receivables	-0.07545M	0.06M	0.28M	-0.24611M	0.47M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	-	-	-	-0.41365M
Change to netincome	-	-	-	0.06M	-0.01640M
Capital expenditures	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.36M	-0.15252M	0.51M	-0.09062M	0.35M
Stock based compensation	-	-	0.00000M	0.00026M	-0.01640M
Other non cash items	0.16M	0.05M	0.02M	0.00304M	-0.00539M
Free cash flow	-0.41019M	-1.02111M	-0.23706M	-0.79878M	-0.36170M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
WAVE Waverley Pharma Inc	0.01 66.67%	0.03	-	-	0.36	1.91	5.07	-4.1071
SHRX Sharp Therapeutics Corp.	- -%	1.00	-	-	-	32.37
NRX NurExone Biologic Inc.	-0.01 1.79%	0.55	-	6.90	-	15.26	-7.2365
MIR MedMira Inc	- -%	0.07	-	-	223.37	-	293.42	-80.0318
TTI Thiogenesis Therapeutics Corp.	- -%	0.56	-	-	-	15.17	-58.1577

Reports Covered

View All

Profile

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Waverley Pharma Inc

4-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6

204 928 7907
https://www.waverleypharma.com

Key Executives

Name	Title	Year Born
Mr. Larry Thiessen	Pres & CEO	NA
Mr. Haaris Uddin B.Com., CPA	Chief Financial Officer	NA
Mr. Larry Thiessen M.B.A.	President, CEO & Director	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.